Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2020
Hereditary amyloidosis community hopes positive funding recommendations for new treatments lead to swift access for patients
2 March 2020 - Hereditary Amyloidosis Canada is joined by the Regroupement québécois des maladies orphelines in commending the CADTH) and ...
Posted by Michael Wonder on 02 Mar 2020
Alberta expands coverage for cystic fibrosis drug
1 March 2020 - It's a step forward but there's a long way to go, says advocate. ...
Posted by Michael Wonder on 26 Feb 2020
N.S. father says drug-pricing 'chess game' cost his daughter her life
25 February 2020 - A father's fight to bring 'life-saving' drugs to Canada. ...
Posted by Michael Wonder on 22 Feb 2020
'Heartbreaking' death of cystic fibrosis patient shines light on drug access issues
21 February 2020 - 23-year-old Chantelle Lindsay died Wednesday after she was denied life saving drug. ...
Posted by Michael Wonder on 18 Feb 2020
Family remains hopeful after request for life-saving drug is denied
16 February 2020 - The past month and a half has been hard on the Lindsay family, as Mark Lindsay ...
Posted by Michael Wonder on 14 Feb 2020
AbbVie's Skyrizi now listed on the Nova Scotia formulary for the treatment of moderate to severe plaque psoriasis
13 February 2020 - Nova Scotia lists Skyrizi on its provincial formulary effective February 06, 2020. ...
Posted by Michael Wonder on 12 Feb 2020
Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s Probuphine to their provincial drug plans in the fight against the opioid crisis
11 February 2020 - Probuphine is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug ...
Posted by Michael Wonder on 09 Feb 2020
N.S. senior blasts province over blood thinner coverage under pharmacare
6 February 2020 - Province covers warfarin, but it requires closer monitoring than newer, more expensive alternative, apixaban. ...
Posted by Michael Wonder on 07 Feb 2020
AbbVie's Skyrizi now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis
6 February 2020 - Skyrizi is the only IL-23 inhibitor to arrive at a positive conclusion with the pCPA and is ...
Posted by Michael Wonder on 31 Jan 2020
When a lottery 'wins' sick babies life-saving drugs
30 January 2020 - Eva was diagnosed with spinal muscular atrophy, a motor neuron disease, just a few weeks after ...
Posted by Michael Wonder on 30 Jan 2020
The life-saving medicine she needs is cheap, common and unavailable in Canadian pharmacies
30 January 2020 - Cassidy Armstrong among a fewer than 200 Canadians who must apply for access. ...
Posted by Michael Wonder on 29 Jan 2020
B.C. eye-injection program ‘clouded in secrecy’
28 January 2020 - Two dozen ophthalmologists are accusing the B.C. government of failing to properly investigate concerns that a ...
Posted by Michael Wonder on 26 Jan 2020
Pickering, Ont. mother living with cystic fibrosis approved for miracle drug: ‘I’m in shock’
24 January 2020 - A Pickering, Ont. mother fighting cystic fibrosis has received her late Christmas wish. ...
Posted by Michael Wonder on 22 Jan 2020
Morneau says Ottawa will need to work with provinces on issues like universal pharmacare
19 January 2020 - Finance Minister Bill Morneau said that the federal government will often need to work together with provinces ...
Posted by Michael Wonder on 19 Jan 2020
Is innovation causing accessibility, timing issues for private drug plans?
17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are ...